Siga Technologies Inc. (SIGA) fundamentals score
Siga Technologies is a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX (“oral TPOXX,” also known as "tecovirimat," "Tecovirimat-SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S. Government and international governments (including government affiliated entities).
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.1 out of 10, Weak long-term fundamentals
- Growth: 3.0/10
- Profitability: 1.4/10
- Financial health: 7.6/10
- Earnings quality: 7.2/10
- Valuation: 2.7/10
Scores are calculated from Siga Technologies Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10